Invasive fungal infections in cancer patients

Clinical Mycology with CD-ROM

Volumn , Issue , 2009, Pages 431-471

  Anaissie, Elias ^a   Grazziutti, Monica ^a   Nucci, Marcio ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919496228     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5680-5/00020-7     Document Type: Chapter

References (264)

1. Wingard J.R. New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients. Best Pract Res Clin Haematol 2007, 20:99-107.
2. Martino R., Subira M., Rovira M., et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002, 116:475-482.
3. Blijlevens N.M., Donnelly J.P., de Pauw B.E. Microbiologic consequences of new approaches to managing hematologic malignancies. Rev Clin Exp Hematol 2005, 9:E2.
4. Pagano L., Caira M., Nosari A., et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007, 45:1161-1170.
5. Almirante B., Rodriguez D., Park B.J., et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005, 43:1829-1835.
6. Bassetti M., Trecarichi E.M., Righi E., et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 2007, 58:325-331.
7. Colombo A.L., Nucci M., Park B.J., et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006, 44:2816-2823.
8. Tortorano A.M., Peman J., Bernhardt H., et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23:317-322.
9. Bow E.J., Loewen R., Cheang M.S., Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995, 21:361-369.
10. Abi-Said D., Anaissie E., Uzun O., Raad I., Pinzcowski H., Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997, 24:1122-1128.
11. De La Rosa G.R., Champlin R.E., Kontoyiannis D.P. Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. Transpl Infect Dis 2002, 4:3-9.
12. Barnes P.D., Marr K.A. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol 2007, 139:519-531.
13. Marr K.A., Seidel K., Slavin M.A., et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000, 96:2055-2061.
14. Muhlemann K., Wenger C., Zenhausern R., Tauber M.G. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005, 19:545-550.
15. Groll A.H., Shah P.M., Mentzel C., Schneider M., Just-Nuebling G., Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996, 33:23-32.
16. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20:133-163.
17. Wingard J.R. The changing face of invasive fungal infections in hematopoietic cell transplant recipients. Curr Opin Oncol 2005, 17:89-92.
18. Boutati E.I., Anaissie E.J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997, 90:999-1008.
19. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., et al. Zygomycosis in a tertiary-care cancer center in the era of Asper gillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350-1360.
20. Kontoyiannis D.P., Wessel V.C., Bodey G.P., Rolston K.V. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000, 30:851-856.
21. Chamilos G., Luna M., Lewis R.E., et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006, 91(7):986-989.
22. Marty F.M., Cosimi L.A., Baden L.R. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004, 350:950-952.
23. Mattner F., Weissbrodt H., Strueber M. Two case reports: fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scand J Infect Dis 2004, 36:312-314.
24. Siwek G.T., Dodgson K.J., de Magalhaes-Silverman M., et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004, 39:584-587.
25. Imhof A., Balajee S.A., Fredricks D.N., Englund J.A., Marr K.A. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004, 39:743-746.
26. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 2005, 40:770-771.
27. Vigouroux S., Morin O., Moreau P., et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005, 40:e35-37.
28. Trifilio S., Singhal S., Williams S., et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007, 40:451-456.
29. Trifilio S.M., Bennett C.L., Yarnold P.R., et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007, 39:425-429.
30. Marr K.A., Crippa F., Leisenring W., et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004, 103:1527-1533.
31. van Burik J.A., Ratanatharathorn V., Stepan D.E., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004, 39:1407-1416.
32. Glasmacher A., Cornely O., Ullmann A.J., et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006, 57:317-325.
33. Oren I., Rowe J.M., Sprecher H., et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006, 38:127-134.
34. Penack O., Schwartz S., Martus P., et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006, 17:1306-1312.
35. Vehreschild J.J., Bohme A., Buchheidt D., et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007, 55:445-449.
36. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356:335-347.
37. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356:348-359.
38. Park BJ, Pappas PG, Marr K, et al. Recent epidemiology of zygomycosis (Z) among solid organ (SOT) and hematopoietic stem cell transplant (SCT) recipients: results from the TRANSNET Surveillance Network. Abstract number M-618. 46th Annual Meeting of the Interscience Conference for Antimicrobial Agents and Chemotherapy, San Francisco, CA. September 27-30, 2006.
39. Anaissie E.J., Stratton S.L., Dignani M.C., et al. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood 2003, 101:2542-2546.
40. Anaissie E.J., Stratton S.L., Dignani M.C., et al. Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. Clin Infect Dis 2002, 35:E86-88.
41. Anaissie E.J., Stratton S.L., Dignani M.C., et al. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 2002, 34:780-789.
42. Munoz P., Bouza E., Cuenca-Estrella M., et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005, 40:1625-1634.
43. Anaissie E.J., Kontoyiannis D.P., O'Brien S., et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998, 129:559-566.
44. Lundin J., Hagberg H., Repp R., et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003, 101:4267-4272.
45. Marty F.M., Lee S.J., Fahey M.M., et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003, 102:2768-2776.
46. Srinivasan R., Chakrabarti S., Walsh T., et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004, 124:777-786.
47. Labbe A.C., Su S.H., Laverdiere M., et al. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant 2007, 13:1192-1200.
48. Wolff D., Roessler V., Steiner B., et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005, 35:1003-1010.
49. Thursky K., Byrnes G., Grigg A., Szer J., Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004, 34:115-121.
50. Mihu C.N., King E., Yossepovitch O., et al. Risk factors and attributable mortality of late aspergillosis after T-cell depleted hematopoietic stem cell transplanation. Transpl Infect Dis 2007.
51. Miceli M.H., Dong L., Grazziutti M.L., et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 2006, 37:857-864.
52. Yates C.R., Krynetski E.Y., Loennechen T., et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997, 126:608-614.
53. Relling M.V., Hancock M.L., Rivera G.K., et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999, 91:2001-2008.
54. Kesh S., Mensah N.Y., Peterlongo P., et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann NY Acad Sci 2005, 1062:95-103.
55. Sainz J., Hassan L., Perez E., et al. Interleukin-10 promoter polymorphism as risk factor to develop invasive pulmonary aspergillosis. Immunol Lett 2007, 109:76-82.
56. Sainz J., Perez E., Hassan L., et al. Variable number of tandem repeats of TNF receptor type 2 promoter as genetic biomarker of susceptibility to develop invasive pulmonary aspergillosis. Hum Immunol 2007, 68:41-50.
57. Granell M., Urbano-Ispizua A., Suarez B., et al. Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Exp Hematol 2006, 34:1435-1441.
58. Sambatakou H., Pravica V., Hutchinson I.V., Denning D.W. Cytokine profiling of pulmonary aspergillosis. Int J Immunogenet 2006, 33:297-302.
59. Van der Graaf C.A., Netea M.G., Morre S.A., et al. Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw 2006, 17:29-34.
60. Meletiadis J., Walsh T.J., Choi E.H., et al. Study of common functional genetic polymorphisms of FCGR2A, 3A and 3B genes and the risk for cryptococcosis in HIV-uninfected patients. Med Mycol 2007, 45:513-518.
61. Carvalho A., Pasqualotto A.C., Pitzurra L., Romani L., Denning D.W., Rodrigues F. Polymorphisms in Toll-like receptor genes and susceptibility to pulmonary aspergillosis. J Infect Dis 2008, 197:618-621.
62. Kobayashi R., Kaneda M., Sato T., Suzuki D., Ichikawa M., Ariga T. Evaluation of risk factors for invasive fungal infection after allogeneic stem cell transplantation in pediatric patients. J Pediatr Hematol Oncol 2007, 29:786-791.
63. Jham B.C., Franca E.C., Oliveira R.R., Santos V.R., Kowalski L.P., da Silva Freire A.R. Candida oral colonization and infection in Brazilian patients undergoing head and neck radiotherapy: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007, 103:355-358.
64. Ezzedine K., Accoceberry I., Malvy D. Oral histoplasmosis after radiation therapy for laryngeal squamous cell carcinoma. J Am Acad Dermatol 2007, 56:871-873.
65. Sung J.M., Ko W.C., Huang J.J. Candidaemia in patients with dialysis-dependent acute renal failure: aetiology, predisposing and prognostic factors. Nephrol Dial Transplant 2001, 16:2348-2356.
66. Abbott K.C., Hypolite I., Tveit D.J., Hshieh P., Cruess D., Agodoa L.Y. Hospitalizations for fungal infections after initiation of chronic dialysis in the United States. Nephron 2001, 89:426-432.
67. Abbas Z., Jafri W., Rasool S., Abid S., Hameed I. Mucormycosis in patients with complicated cirrhosis. Singapore Med J 2007, 48:69-73.
68. Meersseman W., Lagrou K., Maertens J., et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008, 177:27-34.
69. Anaissie E.J. A bad bug takes on a new role as a cause of ventilator-associated pneumonia. Am J Respir Crit Care Med 2008, 177:1-2.
70. Espinel-Ingroff A., Oakley L.A., Kerkering T.M. Opportunistic zygomycotic infections. A literature review. Mycopathologia 1987, 97:33-41.
71. Parikh S.L., Venkatraman G., DelGaudio J.M. Invasive fungal sinusitis: a 15-year review from a single institution. Am J Rhinol 2004, 18:75-81.
72. Simmons J.H., Zeitler P.S., Fenton L.Z., Abzug M.J., Fiallo-Scharer R.V., Klingensmith G.J. Rhinocerebral mucormycosis complicated by internal carotid artery thrombosis in a pediatric patient with type 1 diabetes mellitus: a case report and review of the literature. Pediatr Diabetes 2005, 6:234-238.
73. Pietrangelo A. Iron chelation beyond transfusion iron overload. Am J Hematol 2007, 82:1142-1146.
74. Aisner J., Murillo J., Schimpff S.C., Steere A.C. Invasive aspergillosis in acute leukemia: correlation with nose cultures and antibiotic use. Ann Intern Med 1979, 90:4-9.
75. Guiot H.F., Fibbe W.E., van 't Wout J.W. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994, 18:525-532.
76. Nucci M., Anaissie E. Revisiting the source of candidemia: skin or gut?. Clin Infect Dis 2001, 33:1959-1967.
77. Leong K.W., Crowley B., White B., et al. Cutaneous mucormycosis due to Absidia corymbifera occurring after bone marrow transplantation. Bone Marrow Transplant 1997, 19:513-515.
78. Wirth F., Perry R., Eskenazi A., Schwalbe R., Kao G. Cutaneous mucormycosis with subsequent visceral dissemination in a child with neutropenia: a case report and review of the pediatric literature. J Am Acad Dermatol 1997, 36:336-341.
79. Anaissie E.J., Kuchar R.T., Rex J.H., et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001, 33:1871-1878.
80. Barchiesi F., Caggiano G., Falconi Di Francesco L., Montagna M.T., Barbuti S., Scalise G. Outbreak of fungemia due to Candida parapsilosis in a pediatric oncology unit. Diagn Microbiol Infect Dis 2004, 49:269-271.
81. Babula O., Lazdane G., Kroica J., Ledger W.J., Witkin S.S. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis 2003, 37:733-737.
82. Wingard J.R., Merz W.G., Rinaldi M.G., Miller C.B., Karp J.E., Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993, 37:1847-1849.
83. Wingard J.R. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995, 20:115-125.
84. Wingard J.R. Antifungal chemoprophylaxis after blood and marrow transplantation. Clin Infect Dis 2002, 34:1386-1390.
85. Hovi L., Saarinen-Pihkala U.M., Vettenranta K., Saxen H. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant 2000, 26:999-1004.
86. Barton T., Collis T., Stadtmauer E., Schuster M. Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis 2001, 32:391-395.
87. Marr K.A., Carter R.A., Crippa F., Wald A., Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34:909-917.
88. Nucci M., Marr K.A., Queiroz-Telles F., et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004, 38:1237-1242.
89. Junghanss C., Marr K.A., Carter R.A., et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002, 8:512-520.
90. Wald A., Leisenring W., van Burik J.A., Bowden R.A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997, 175:1459-1466.
91. Dvorak C.C., Steinbach W.J., Brown J.M., Agarwal R. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2005, 36:621-629.
92. Anaissie E., Bodey G.P., Kantarjian H., et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991, 91:142-150.
93. Marr K.A., Carter R.A., Boeckh M., Martin P., Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002, 100:4358-4366.
94. Stergiopoulou T., Meletiadis J., Roilides E., et al. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol 2007, 127:349-355.
95. Vartivarian S.E., Anaissie E.J., Bodey G.P. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis 1993, 17(suppl 2):S487-491.
96. Anaissie E.J., Bodey G.P., Rinaldi M.G. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis 1989, 8:323-330.
97. Coleman D.C., Rinaldi M.G., Haynes K.A., et al. Importance of Candida species other than Candida albicans as opportunistic pathogens. Med Mycol 1998, 36(suppl 1):156-165.
98. Anaissie E.J., Darouiche R.O., Abi-Said D., et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996, 23:964-972.
99. Nucci M., Colombo A.L. Candidemia due to Candida tropicalis: clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals. Diagn Microbiol Infect Dis 2007, 58:77-82.
100. Viscoli C., Girmenia C., Marinus A., et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999, 28:1071-1079.
101. Nucci M., Pulcheri W., Spector N., et al. Cutaneous involvement of systemic fungal infections in neutropenic patients. Haematologica 1992, 77:522-523.
102. Girmenia C., Martino P., De Bernardis F., et al. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis 1996, 23:506-514.
103. Grow W.B., Moreb J.S., Roque D., et al. Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002, 29:15-19.
104. Lortholary O., Ascioglu S., Moreau P., et al. Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergroupe Francais du Myelome. Clin Infect Dis 2000, 30:41-46.
105. Koneru B., Hough A., Fassas A., et al. Autopsy review in multiple myeloma reveals aspergillosis as a significant cause of death after high dose therapy especially allotransplants. Blood 1997, 90:353.
106. Nucci M., Anaissie E.J., Queiroz-Telles F., et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003, 98:315-319.
107. Spellberg B., Edwards J., Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005, 18:556-569.
108. O'Bryan T.A. Pseudallescheriasis in the 21st century. Expert Rev Anti Infect Ther 2005, 3:765-773.
109. Panackal A.A., Marr K.A. Scedosporium/Pseudallescheria infections. Semin Respir Crit Care Med 2004, 25:171-181.
110. Bouza E., Munoz P. Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. Clin Microbiol Infect 2004, 10(suppl 1):76-85.
111. Husain S., Munoz P., Forrest G., et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005, 40:89-99.
112. Pagano L., Fianchi L., Caramatti C., et al. Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection. Haematologica 2004, 89:852-856.
113. Kunova A., Krcmery V. Fungaemia due to thermophilic cryptococci: 3 cases of Cryptococcus laurentii bloodstream infections in cancer patients receiving antifungals. Scand J Infect Dis 1999, 31:328.
114. Ramchandren R., Gladstone D.E. Cryptococcus albidus infection in a patient undergoing autologous progenitor cell transplant. Transplantation 2004, 77:956.
115. Anaissie E., Gokaslan A., Hachem R., et al. Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis 1992, 15:781-787.
116. Girmenia C., Pagano L., Martino B., et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005, 43:1818-1828.
117. Lunardi L.W., Aquino V.R., Zimerman R.A., Goldani L.Z. Epidemiology and outcome of Rhodotorula fungemia in a tertiary care hospital. Clin Infect Dis 2006, 43:e60-63.
118. Jahagirdar B.N., Morrison V.A. Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients. Semin Respir Infect 2002, 17:113-120.
119. Blair J.E., Smilack J.D., Caples S.M. Coccidioidomycosis in patients with hematologic malignancies. Arch Intern Med 2005, 165:113-117.
120. Adderson E.E. Histoplasmosis in a pediatric oncology center. J Pediatr 2004, 144:100-106.
121. Miceli M.H., Maertens J., Buve K., et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 2007, 110:112-120.
122. Stynen D., Goris A., Sarfati J., Latge J.P. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 1995, 33:497-500.
123. Maertens J., Van Eldere J., Verhaegen J., Verbeken E., Verschakelen J., Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002, 186:1297-1306.
124. Ascioglu S., Rex J.H., de Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002, 34:7-14.
125. Maertens J., Theunissen K., Verhoef G., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005, 41:1242-1250.
126. Marr K.A., Leisenring W. Design issues in studies evaluating diagnostic tests for aspergillosis. Clin Infect Dis 2005, 41(suppl 6):S381-386.
127. Aquino V.R., Goldani L.Z., Pasqualotto A.C. Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis. Mycopathologia 2007, 163:191-202.
128. Walsh T.J., Shoham S., Petraitiene R., et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol 2004, 42:4744-4748.
129. Pfeiffer C.D., Fine J.P., Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006, 42:1417-1427.
130. Penack O., Rempf P., Graf B., Thiel E., Blau I.W. False-positive Aspergillus antigen testing due to application of piperacillin/tazobactam-is it still an issue?. Diagn Microbiol Infect Dis 2008, 60:117-120.
131. Racil Z., Kocmanova I., Lengerova M., Winterova J., Mayer J. Intravenous PLASMA-LYTE as a major cause of false-positive results of platelia Aspergillus test for galactomannan detection in serum. J Clin Microbiol 2007, 45:3141-3142.
132. Anaissie E.J. Trial design for mold-active agents: time to break the mold-aspergillosis in neutropenic adults. Clin Infect Dis 2007, 44:1298-1306.
133. Cummings J.R., Jamison G.R., Boudreaux J.W., Howles M.J., Walsh T.J., Hayden R.T. Cross-reactivity of non-Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassay. Diagn Microbiol Infect Dis 2007, 59:113-115.
134. Miceli M.H., Anaissie E.J. When a paradoxical increase in serum galactomannan antigen during caspofungin therapy is not paradoxical after all. Clin Infect Dis 2007, 44:757-760. author reply 760-761.
135. Woods G., Miceli M.H., Grazziutti M.L., Zhao W., Barlogie B., Anaissie E. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 2007, 110:830-834.
136. Miceli M., Grazziutti M., Woods G., Kokoglu M.H., Barlogie B., Anaissie E. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008, 46.
137. Odabasi Z., Mattiuzzi G., Estey E., et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004, 39:199-205.
138. Ostrosky-Zeichner L., Alexander B.D., Kett D.H., et al. Multicenter clinical evaluation of the (1>3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005, 41:654-659.
139. Senn L., Robinson J.O., Schmidt S., et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008, 46:878-885.
140. Herbrecht R., Berceanu A. Beta-D-glucan detection test: a step toward preemptive therapy for fungal infections in leukemic patients?. Clin Infect Dis 2008, 46:886-889.
141. Wazir J.F., Ansari N.A. Pneumocystis carinii infection. Update and review. Arch Pathol Lab Med 2004, 128:1023-1027.
142. Akamatsu N., Sugawara Y., Kaneko J., Tamura S., Makuuchi M. Preemptive treatment of fungal infection based on plasma (1-3)beta-D-glucan levels after liver transplantation. Infection 2007, 35:346-351.
143. Marty F.M., Koo S., Bryar J., Baden L.R. (1>3)beta-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med 2007, 147:70-72.
144. Kawagishi N., Miyagi S., Satoh K., Akamatsu Y., Sekiguchi S., Satomi S. Usefulness of beta-D glucan in diagnosing Pneumocystis carinii pneumonia and monitoring its treatment in a living-donor liver-transplant recipient. J Hepatobiliary Pancreat Surg 2007, 14:308-311.
145. Tasaka S., Hasegawa N., Kobayashi S., et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest 2007, 131:1173-1180.
146. Shimizu A., Oka H., Matsuda T., Ozaki S. (1>3)-beta-D glucan is a diagnostic and negative prognostic marker for Pneumocystis carinii pneumonia in patients with connective tissue disease. Clin Exp Rheumatol 2005, 23:678-680.
147. Teramoto S., Sawaki D., Okada S., Ouchi Y. Markedly increased plasma (1>3)-beta-D-glucan is a diagnostic and therapeutic indicator of Pneumocystis carinii pneumonia in a non-AIDS patient. J Med Microbiol 2000, 49:393-394.
148. Murakami T., Suzuki M., Okada S., et al. Pneumocystis carinii pneumonia associated with acquired immunodeficiency syndrome followed by KL-6, surfactant protein-D and beta-D-glucan in serum). Nihon Kokyuki Gakkai Zasshi 2000, 38:632-636.
149. Hauggaard A., Ellis M., Ekelund L. Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis. Acta Radiol 2002, 43:292-298.
150. Greene R. The radiological spectrum of pulmonary aspergillosis. Med Mycol 2005, 43(suppl 1):S147-154.
151. Pinto P.S. The CT halo sign. Radiology 2004, 230:109-110.
152. Lee Y.R., Choi Y.W., Lee K.J., Jeon S.C., Park C.K., Heo J.N. CT halo sign: the spectrum of pulmonary diseases. Br J Radiol 2005, 78:862-865.
153. Horger M., Einsele H., Schumacher U., et al. Invasive pulmonary aspergillosis: frequency and meaning of the "hypodense sign" on unenhanced CT. Br J Radiol 2005, 78:697-703.
154. Shirkhoda A. CT findings in hepatosplenic and renal candidiasis. J Comput Assist Tomogr 1987, 11:795-798.
155. Shirkhoda A., Lopez-Berestein G., Holbert J.M., Luna M.A. Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B. Radiology 1986, 159:349-353.
156. Halkic N., Ksontini R. Images in clinical medicine. Hepatosplenic candidiasis. N Engl J Med 2007, 356:e4.
157. Mahfouz T., Miceli M.H., Saghafifar F., et al. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol 2005, 23:7857-7863.
158. Miceli M., Atoui R., Thertulien R., et al. Deep septic thrombophlebitis: an unrecognized cause of relapsing bacteremia in patients with cancer. J Clin Oncol 2004, 22:1529-1531.
159. Miceli M., Atoui R., Walker R., et al. Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 fluorodeoxyglucose positron emission tomography scanning: a preliminary report. J Clin Oncol 2004, 22:1949-1956.
160. Subira M., Martino R., Rovira M., Vazquez L., Serrano D., De La Camara R. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. Ann Hematol 2003, 82:80-82.
161. Denning D.W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996, 23:608-615.
162. Todeschini G., Murari C., Bonesi R., et al. Invasive aspergillosis in neutropenic patients: rapid neutrophil recovery is a risk factor for severe pulmonary complications. Eur J Clin Invest 1999, 29:453-457.
163. Caillot D., Couaillier J.F., Bernard A., et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001, 19:253-259.
164. Kramer M.R., Denning D.W., Marshall S.E., et al. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis 1991, 144:552-556.
165. Logan P.M., Primack S.L., Miller R.R., Muller N.L. Invasive aspergillosis of the airways: radiographic, CT, and pathologic findings. Radiology 1994, 193:383-388.
166. Putnam J.B., Dignani C., Mehra R.C., Anaisse E.J., Morice R.C., Libshitz H.I. Acute airway obstruction and necrotizing tracheobronchitis from invasive mycosis. Chest 1994, 106:1265-1267.
167. Dubois P.J., Myerowitz R.L., Allen C.M. Pathoradiologic correlation of pulmonary candidiasis in immunosuppressed patients. Cancer 1977, 40:1026-1036.
168. Buff S.J., McLelland R., Gallis H.A., Matthay R., Putman C.E. Candida albicans pneumonia: radiographic appearance. Am J Roentgenol 1982, 138:645-648.
169. Saito H., Anaissie E.J., Morice R.C., Dekmezian R., Bodey G.P. Bronchoalveolar lavage in the diagnosis of pulmonary infiltrates in patients with acute leukemia. Chest 1988, 94:745-749.
170. Siemann M., Koch-Dorfler M. The Platelia Aspergillus ELISA in diagnosis of invasive pulmonary aspergilosis (IPA). Mycoses 2001, 44:266-272.
171. Musher B., Fredricks D., Leisenring W., Balajee S.A., Smith C., Marr K.A. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004, 42:5517-5522.
172. Becker M.J., Lugtenburg E.J., Cornelissen J.J., Van Der Schee C., Hoogsteden H.C., De Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003, 121:448-457.
173. Mafee M.F., Tran B.H., Chapa A.R. Imaging of rhinosinusitis and its complications: plain film, CT, and MRI. Clin Rev Allergy Immunol 2006, 30:165-186.
174. Zinreich S.J., Kennedy D.W., Malat J., et al. Fungal sinusitis: diagnosis with CT and MR imaging. Radiology 1988, 169:439-444.
175. Mattiuzzi G., Giles F.J. Management of intracranial fungal infections in patients with haematological malignancies. Br J Haematol 2005, 131:287-300.
176. Mays S.R., Bogle M.A., Bodey G.P. Cutaneous fungal infections in the oncology patient: recognition and management. Am J Clin Dermatol 2006, 7:31-43.
177. Nucci M., Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002, 35:909-920.
178. Prescott R.J., Harris M., Banerjee S.S. Fungal infections of the small and large intestine. J Clin Pathol 1992, 45:806-811.
179. Tresallet C., Nguyen-Thanh Q., Aubriot-Lorton M.H., et al. Small-bowel infarction from disseminated aspergillosis. Dis Colon Rectum 2004, 47:1515-1518.
180. Cohen R., Heffner J.E. Bowel infarction as the initial manifestation of disseminated aspergillosis. Chest 1992, 101:877-879.
181. Shah S.S., Birnbaum B.A., Jacobs J.E. Disseminated aspergillosis inciting intestinal ischaemia and obstruction. Br J Radiol 2001, 74:1145-1147.
182. Foy T.M., Hawkins E.P., Peters K.R., Shearer W., Ferry G.D. Colonic ulcers and lower GI bleeding due to disseminated aspergillosis. J Pediatr Gastroenterol Nutr 1994, 18:399-403.
183. Grigg A., Slavin M. Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy. Transpl Infect Dis 2008, 10:3-12.
184. Cesaro S., Cecchetto G., De Corti F., et al. Results of a multicenter retrospective study of a combined medical and surgical approach to pulmonary aspergillosis in pediatric neutropenic patients. Pediatr Blood Cancer 2007, 49:909-913.
185. Nosari A., Ravini M., Cairoli R., et al. Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia. Bone Marrow Transplant 2007, 39:631-635.
186. Albert R.K., Condie F. Hand-washing patterns in medical intensive-care units. N Engl J Med 1981, 304:1465-1466.
187. Humphreys H. Positive-pressure isolation and the prevention of invasive aspergillosis. What is the evidence?. J Hosp Infect 2004, 56:93-100. quiz 163.
188. Lee L.D., Berkheiser M., Jiang Y., et al. Risk of bioaerosol contamination with Aspergillus species before and after cleaning in rooms filtered with high-efficiency particulate air filters that house patients with hematologic malignancy. Infect Control Hosp Epidemiol 2007, 28:1066-1070.
189. Nihtinen A., Anttila V.J., Richardson M., Meri T., Volin L., Ruutu T. The utility of intensified environmental surveillance for pathogenic moulds in a stem cell transplantation ward during construction work to monitor the efficacy of HEPA filtration. Bone Marrow Transplant 2007, 40:457-460.
190. Dignani M.C., Rex J.H., Chan K.W., et al. Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia. Cancer 2005, 104:199-204.
191. Dignani M.C., Anaissie E.J., Hester J.P., et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997, 11:1621-1630.
192. Jendiroba D.B., Freireich E.J. Granulocyte transfusions: from neutrophil replacement to immunereconstitution. Blood Review 2000, 14:219-227.
193. Grigull L., Schrauder A., Schmitt-Thomssen A., Sykora K., Welte K. Efficacy and safety of G-CSF mobilized granulocyte transfusions in four neutropenic children with sepsis and invasive fungal infection. Infection 2002, 30:267-271.
194. Spielberger R., Stiff P., Bensinger W., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004, 351:2590-2598.
195. Slavin M.A., Osborne B., Adams R., et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995, 171:1545-1552.
196. Benson C.A., Kaplan J.E., Masur H., Pau A., Holmes K.K. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004, 53:1-112.
197. Gubbins P.O. Mould-active azoles: pharmacokinetics, drug interactions in neutropenic patients. Curr Opin Infect Dis 2007, 20:579-586.
198. Gubbins P.O., Penzak S.R., Polston S., McConnell S.A., Anaissie E. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 2002, 22:961-971.
199. Robenshtok E., Gafter-Gvili A., Goldberg E., et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007, 25:5471-5489.
200. Bow E.J., Laverdiere M., Lussier N., Rotstein C., Cheang M.S., Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002, 94:3230-3246.
201. Mahfouz T., Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Invest Drugs 2003, 4:974-990.
202. Rex J.H., Anaissie E.J., Boutati E., Estey E., Kantarjian H. Systemic antifungal prophylaxis reduces invasive fungal in acute myelogenous leukemia: a retrospective review of 833 episodes of neutropenia in 322 adults. Leukemia 2002, 16:1197-1199.
203. Goodman J.L., Winston D.J., Greenfield R.A., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992, 326:845-851.
204. Laverdiere M., Rotstein C., Bow E.J., et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. J Antimicrob Chemother 2000, 46:1001-1008.
205. Glasmacher A., Prentice A., Gorschluter M., et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003, 21:4615-4626.
206. Vardakas K.Z., Michalopoulos A., Falagas M.E. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005, 131:22-28.
207. Winston D.J., Maziarz R.T., Chandrasekar P.H., et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003, 138:705-713.
208. Segal B.H., Almyroudis N.G., Battiwalla M., et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007, 44:402-409.
209. Wingard J.R. Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. Clin Infect Dis 2004, 39(Suppl. 4):S176-180.
210. Schwartz S., Behre G., Heinemann V., et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999, 93:3654-3661.
211. Palmer S.M., Drew R.H., Whitehouse J.D., et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001, 72:545-548.
212. Monforte V., Roman A., Gavalda J., et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001, 20:1274-1281.
213. Rijnders B.J., Cornelissen J.J., Slobbe L., et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008, 46:1401-1408.
214. Offner F., Cordonnier C., Ljungman P., et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998, 26:1098-1103.
215. Sipsas N.V., Kontoyiannis D.P. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis 2006, 42:1584-1591.
216. Allinson K., Kolve H., Gumbinger H.G., Vormoor H.J., Ehlert K., Groll A.H. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother 2008, 61:734-742.
217. de Fabritiis P., Spagnoli A., Di Bartolomeo P., et al. Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant 2007, 40:245-249.
218. Fukuda T., Boeckh M., Guthrie K.A., et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004, 10:494-503.
219. Pizzo P.A., Robichaud K.J., Gill F.A., Witebsky F.G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982, 72:101-111.
220. Walsh T.J., Lee J., Lecciones J., et al. Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 1991, 13:496-503.
221. Malik I.A., Moid I., Aziz Z., Khan S., Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998, 105:478-483.
222. Winston D.J., Hathorn J.W., Schuster M.G., Schiller G.J., Territo M.C. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000, 108:282-289.
223. White M.H., Bowden R.A., Sandler E.S., et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998, 27:296-302.
224. Mehta J., Kelsey S., Chu P., et al. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transplant 1997, 20:39-43.
225. Walsh T.J., Finberg R.W., Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999, 340:764-771.
226. Schuler U., Bammer S., Aulitzky W.E., et al. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Onkologie 2007, 30:185-191.
227. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002, 346:225-234.
228. Walsh T.J., Teppler H., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004, 351:1391-1402.
229. Sobel J.D. Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques. Pharmacotherapy 2006, 26:47S-54S.
230. Maertens J., Deeren D., Dierickx D., Theunissen K. Preemptive antifungal therapy: still a way to go. Curr Opin Infect Dis 2006, 19:551-556.
231. Ullmann A.J., Sanz M.A., Tramarin A., et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006, 43:e29-38.
232. Wingard J.R., White M.H., Anaissie E., Raffalli J., Goodman J., Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000, 31:1155-1163.
233. Kullberg B.J., Sobel J.D., Ruhnke M., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005, 366:1435-1442.
234. Kuse E.R., Chetchotisakd P., da Cunha C.A., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007, 369:1519-1527.
235. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347:2020-2029.
236. Pappas P.G., Rotstein C.M., Betts R.F., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45:883-893.
237. Phillips P., Shafran S., Garber G., et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997, 16:337-345.
238. Reboli A.C., Rotstein C., Pappas P.G., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356:2472-2482.
239. Rex J.H., Pappas P.G., Karchmer A.W., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003, 36:1221-1228.
240. Rex J.H., Bennett J.E., Sugar A.M., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994, 331:1325-1330.
241. Marr K.A. The changing spectrum of candidemia in oncology patients: therapeutic implications. Curr Opin Infect Dis 2000, 13:615-620.
242. Marr K.A., Seidel K., White T.C., Bowden R.A. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000, 181:309-316.
243. Nucci M., Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 2002, 34:591-599.
244. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
245. Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther 2004, 2:485-497.
246. Cornely O.A., Maertens J., Bresnik M., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007, 44:1289-1297.
247. Marr K.A., Boeckh M., Carter R.A., Kim H.W., Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797-802.
248. Caillot D., Thiebaut A., Herbrecht R., et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007, 110:2740-2746.
249. Spellberg B., Fu Y., Edwards J.E., Ibrahim A.S. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005, 49:830-832.
250. Greenberg R.N., Mullane K., van Burik J.A., et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50:126-133.
251. van Burik J.A., Hare R.S., Solomon H.F., Corrado M.L., Kontoyiannis D.P. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42:e61-65.
252. Nucci M., Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007, 20:695-704.
253. DiNubile M.J., Hille D., Sable C.A., Kartsonis N.A. Invasive candidiasis in cancer patients: observations from a randomized clinical trial. J Infect 2005, 50:443-449.
254. Pagano L., Caira M., Candoni A., et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006, 91:1068-1075.
255. Nucci M., Silveira M.I., Spector N., et al. Risk factors for death among cancer patients with fungemia. Clin Infect Dis 1998, 27:107-111.
256. Anaissie E.J., Rex J.H., Uzun O., Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998, 104:238-245.
257. Uzun O., Ascioglu S., Anaissie E.J., Rex J.H. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 2001, 32:1713-1717.
258. Subira M., Martino R., Franquet T., et al. Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors. Haematologica 2002, 87:528-534.
259. Upton A., Kirby K.A., Carpenter P., Boeckh M., Marr K.A. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007, 44:531-540.
260. Pagano L., Offidani M., Fianchi L., et al. Mucormycosis in hematologic patients. Haematologica 2004, 89:207-214.
261. Maschmeyer G., Bertschat F.L., Moesta K.T., et al. Outcome analysis of 189 consecutive cancer patients referred to the intensive care unit as emergencies during a 2-year period. Eur J Cancer 2003, 39:783-792.
262. Uzun O., Anaissie E.J. Predictors of outcome in cancer patients with candidemia. Ann Oncol 2000, 11:1517-1521.
263. Ribaud P., Chastang C., Latge J.P., et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999, 28:322-330.
264. Cordonnier C., Ribaud P., Herbrecht R., et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006, 42:955-963.